A bulk drug substance is the active ingredient used to make a medicine, before it becomes a finished dose. It's also called an active pharmaceutical ingredient, or API—the part intended to produce the medicine's effect.
If “what is a bulk drug substance” came up while reading about peptides, “bulk” doesn't mean a bigger injection. It means the pharmacy's starting ingredient. The finished prescription still needs the right formulation, strength and label.
What is a bulk drug substance in FDA language?
The U.S. Food and Drug Administration (FDA) uses these two names for the same thing. 21 CFR 207.3, the federal drug regulation, points to the API definition in 21 CFR 207.1.
That definition describes a substance intended to become part of a finished drug and produce a direct effect in the body. It excludes chemicals used only as steps in making that substance.
An excipient is a supporting ingredient, such as a liquid used to dissolve the active ingredient. A finished drug product is the prepared medicine in its final package. A large bottle of finished tablets isn't an API simply because someone calls it “bulk.”
Why pharmacies have ingredient rules
Compounding means preparing a medicine by combining or altering ingredients. The ingredient rules distinguish what a pharmacy can start with from the finished preparation it dispenses.
Section 503A is the federal pathway for traditional compounding for an identified patient. It includes limits on which starting ingredients a pharmacy can use.
Peptides nominated to a compounding list
Peptides are short chains of amino acids, the building blocks of proteins. A nomination is a request for FDA to consider adding an ingredient to a compounding list.
As of September 30, 2026, the day this article was written, FDA's July committee agenda, marked “Updated Information (as of 7/14/2026),” identifies two BPC-157 chemical forms for review: free base and acetate.
The committee gives advice. Its review doesn't itself add an ingredient to the final list or approve a finished medicine. A BPC-157 prescription concerns a particular preparation and patient, not just a molecule's name on an agenda.
The three 503A bulk ingredient routes
A monograph is an official ingredient standard. USP and NF stand for United States Pharmacopeia and National Formulary, the collections containing those standards.
As of September 30, 2026, the day this article was written, FDA's 503A ingredient overview, marked “Content current as of: 05/14/2026,” describes three routes:
| Starting point | Ingredient requirement |
|---|---|
| An applicable USP or NF monograph exists | The substance complies with it and the USP chapter on pharmacy compounding. |
| No applicable monograph exists | A component of an FDA-approved drug. |
| Neither of those routes applies | The substance appears on the final 503A bulks list. |
Meeting an ingredient requirement doesn't settle every condition for compounding a prescription. Sourcing, the prescription and the finished preparation have requirements too.
How the distinction shows up in a semaglutide prescription
Semaglutide makes the difference concrete. The API is the active ingredient. The finished preparation also has a concentration—the amount of drug in a given volume—and a label identifying that preparation.
The chemical form matters before any of those later steps. As of September 30, 2026, the day this article was written, FDA's GLP-1 information page, marked “Content current as of: 09/01/2026,” distinguishes semaglutide sodium and semaglutide acetate from the active ingredient in branded medicines. GLP-1 is a gut hormone involved in appetite and blood sugar.
FDA says it lacks information showing that those salts have the same chemical and drug effects. A salt form is a chemical version paired with another charged component. FDA also says it is not aware of a lawful basis for using these salt forms in compounding.
Seeing “semaglutide” on paperwork isn't enough to establish which ingredient it names.
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which are different from FDA-approved products: the formulations offered here are not FDA-approved.
Why the source and certificate of analysis matter
A certificate of analysis, or COA, reports test results for a particular batch. Both 503A and 503B ingredient rules require a valid certificate and a manufacturer registered with FDA. The 503B page is marked “Content current as of: 01/07/2025.”
FDA's API manufacturing guidance, section 11.4, describes what belongs on that certificate: the ingredient, batch number, tests, acceptance limits and results. It also calls for the original manufacturer's identity.
Those details connect the test report to the actual material. A purity percentage alone doesn't identify the batch, explain which tests were performed or establish that an injection is sterile—free of living microorganisms.
As of September 30, 2026, the day this article was written, FDA's Import Alert 66-80 carries “Published Date: 09/21/2026.” It describes border checks for GLP-1 ingredients and a Green List of manufacturer-and-product exceptions. FDA reports noncompliance at about 1 in 5 evaluated ingredient sites: 21% of the 48 it examined. The finding included failures to provide requested records. It concerns those sites; it isn't a failure rate for patients' prescriptions.
Actual product testing shows why a name alone isn't enough. In a 2024 JAMA Network Open study by Ashraf and colleagues, three products received from sellers requiring no prescription contained roughly a third more semaglutide than stated: 29%–39% more. Those three samples don't represent every seller or a licensed pharmacy's output.
Mistakes people make with ingredient paperwork
Treating a certificate as proof about the finished medicine. An API certificate concerns the starting batch. It doesn't, by itself, establish the finished preparation's concentration, sterility or storage conditions.
Assuming a correct ingredient prevents dosing confusion. A 2023 case series by Lambson and colleagues in the Journal of the American Pharmacists Association described three semaglutide administration errors involving products from compounding pharmacies and an aesthetic spa. Two people administered ten times the intended amount. This small report shows why clear labeling and counseling matter after sourcing, too.
Expecting a supplier's document to set a prescription. For tirzepatide, the ingredient's identity and the finished medicine's strength are separate details. The provider sets the prescribed dose; the pharmacy prepares and labels the formulation. The same distinction applies even when an ingredient certificate is complete.
Related terms for the prescription conversation
The 503A bulks list is one ingredient route, not a catalog of every medicine a pharmacy compounds. FDA Category 2 describes an interim policy group for nominated ingredients with identified safety concerns.
A 503B outsourcing facility is a registered compounding operation that can supply qualifying clinic stock. It uses a separate bulks list based on clinical need. The other statutory bulk-ingredient route concerns medicines on FDA's shortage list when compounded, distributed and dispensed. A 503A list position doesn't transfer to 503B.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. The pharmacy separately checks the ingredient and preparation requirements.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful prescription record identifies the exact medicine, dispensing pharmacy and contact for questions after the visit.
